AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021

Jun 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-06-21

Reporting Person: Alenson Carman (Principal Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-21	Common stock	M	1777	$51.51	Acquired	1777	Direct
2021-06-21	Common stock	S	1777	$61.61	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-21	Stock option (right to buy)	$51.51	M	1777	Disposed	2030-02-14	Common stock (1777.0)	Direct

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.